
Browsing restrictions can be lifted for a fee.
-0.74%
Profound medical corp.
-1.10%
Avg of Sector
-0.49%
S&P500
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2025Q4 | |||||||
| 2025Q3 | |||||||
| 2025Q2 | |||||||
| 2025Q1 |
The most recent financial report for Profound medical corp. (PROF) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating PROF's short-term business performance and financial health. For the latest updates on PROF's earnings releases, visit this page regularly.
According to the latest financial report, Profound medical corp. (PROF) reported an Operating Profit of -7.37M with an Operating Margin of -123.29% this period, representing a growth of 15.87% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
In the latest financial report, Profound medical corp. (PROF) announced revenue of 5.98M, with a Year-Over-Year growth rate of 61.32%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
As of the end of the reporting period, Profound medical corp. (PROF) had total debt of 4.71M, with a debt ratio of 0.06. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
At the end of the period, Profound medical corp. (PROF) held Total Cash and Cash Equivalents of 59.72M, accounting for 0.77 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
In the latest report, Profound medical corp. (PROF) did not achieve the “three margins increasing” benchmark, with a gross margin of 66.8%%, operating margin of -123.29%%, and net margin of -136.8%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess PROF's profit trajectory and future growth potential.
According to the past four quarterly reports, Profound medical corp. (PROF)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.27. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
Profound medical corp. (PROF)'s Free Cash Flow (FCF) for the period is -6.57M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 16.38% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.